Categories Covered:Pregnancy, Childbirth, and HIV, HIV Treatment Strategies, FDA-Approved HIV Medications, Efavirenz (Sustiva, Stocrin), First-Line HIV Treatment, HIV Epidemiology, Managing HIV Drug Resistance, HIV Care and Services Outside the US, Etravirine (Intelence), Maraviroc (Selzentry, Celsentri), Providing Quality HIV Care, Meeting the Costs of HIV Care, Raltegravir (Isentress), Darunavir (Prezista), Adverse Events, Comorbidities, and HIV, Lopinavir/Ritonavir (Kaletra), Fosamprenavir (Lexiva, Telzir), Dolutegravir (Tivicay), Switching or Stopping HIV Treatment, PrEP (HIV Pre-Exposure Prophylaxis), Tenofovir Disoproxil Fumarate (Viread), Zidovudine (AZT, Retrovir), Rilpivirine (Edurant), HIV Treatments in Development, HIV Prevention Methods, Atazanavir (Reyataz), HIV Testing, Nevirapine (Viramune), Pediatric HIV Care, U=U (Undetectable Equals Untransmittable, i.e. HIV Treatment as Prevention), Abacavir/Lamivudine (Epzicom, Kivexa), Managing People Newly Diagnosed With HIV, HIV Care Continuum, Managing Primary/Acute HIV Infection, Managing Long-Term HIV Survivors, Stavudine (d4T, Zerit), Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada), Elvitegravir (Vitekta), HIV Policy and Advocacy
Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.
"It is hard to imagine how in 2018 we could be in this situation where women with HIV are being so woefully underserved," Polly Clayden writes.
A recent case study illustrates the complexity of managing women in early stages of pregnancy presenting on a dolutegravir-based regimen, and the need for careful consideration when responding to new data.
Drug-drug interactions and side effects, associated with currently-used first-line antiretroviral therapy, are under-reported and managed in Uganda.
Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.
24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.
A review of the effect of rifampin on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics presented at CROI 2018.
Dolutegravir (Tivicay) given with once-weekly isoniazid-rifapentine led to marked cytokine release and serious adverse events in a drug-drug interaction study.
Steady advances reported in HIV i-Base's HIV Treatment Bulletin in 2017 were broadly categorized as great news. These are important given the political change and uncertainty over the year.
Meta-analysis of randomized trials presented at EACS 2017 found a slightly higher risk of insomnia for dolutegravir compared with other antiretrovirals, but no difference for other CNS side effects.